Guardant Health, Inc.
GH Nasdaq· Services-Medical Laboratories
Last close · Oct 26, 2026
$173.25
KIRA · Stoqly’s AI analyst, in plain words
- Guardant Health, Inc. had $982M of revenue in fiscal 2025, up 32.9% on the year before. Over five years, revenue changed +27.9% a year on average.
- Its operating margin was −44.5%, up 15.5 pts: of every 100 in sales, about −45 is left after running the business.
- Guardant Health, Inc. lost $416M in fiscal 2025.
- Free cash flow was −$233M in fiscal 2025, −23.7% of revenue.
- Guardant Health, Inc. returned $45.0M to shareholders in fiscal 2025. The diluted share count rose 2.1%.
- Guardant Health, Inc. owes $302M more than it holds in cash.
Market cap
$23.0B
P/E
—
Revenue
$982M
Net income
−$416M
Free cash flow
−$233M
Operating margin
−44.5%
Guardant Health, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+32.9%
Yes. Sales grew 32.9% last year.
Does it make a profit?
−42.4%
No. It lost money last year.
Does profit turn into cash?
−23.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Guardant Health, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- Guardant Health, Inc.
- CIK
- 0001576280
Guardant Health, Inc. · GH
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $374M | $450M | $564M | $739M | $982M |
| Revenue growth | 30.3% | 20.3% | 25.5% | 31.0% | 32.9% |
| Gross margin | — | — | 59.7% | 60.8% | 64.5% |
| Operating margin | −110.0% | −121.1% | −100.1% | −60.0% | −44.5% |
| Net income | −$385M | −$655M | −$479M | −$436M | −$416M |
| Net margin | −103.0% | −145.6% | −85.0% | −59.0% | −42.4% |
| Diluted EPS | −$4.00 | −$6.41 | −$4.28 | −$3.56 | −$3.32 |
| Cash | |||||
| Cash from operations | −$209M | −$309M | −$325M | −$240M | −$185M |
| Capital expenditure | $75.0M | $77.5M | $20.5M | $35.1M | $48.3M |
| Free cash flow | −$284M | −$387M | −$345M | −$275M | −$233M |
| FCF margin | −76.0% | −86.1% | −61.3% | −37.2% | −23.7% |
| Share buybacks | — | — | $0.0M | $0.0M | $45.0M |
| Share count change | 3.9% | 0.9% | 9.6% | 9.6% | 2.1% |
| Debt and strength | |||||
| Cash and short-term investments | $933M | $1.0B | $1.2B | $840M | $1.2B |
| Debt incl. finance leases | — | — | — | $1.1B | $1.5B |
| Shareholders' equity | $645M | $60.2M | $159M | −$140M | −$99.3M |
| Current ratio | 5.7x | 6.2x | 6.5x | 4.7x | 4.8x |
| Interest coverage | −159.5x | −211.2x | −219.1x | −171.9x | −112.2x |
| Returns and quality | |||||
| Return on capital | — | — | — | −215.1% | −170.1% |
| Return on equity | −39.6% | −185.7% | −438.1% | −4,584.5% | — |
| Return on tangible equity | −64.6% | −1,449.4% | −327.5% | — | — |
| Piotroski F-score | 2 | 3 | 4 | 3 | 5 |
| Altman Z'' | 0.4 | −1.5 | −1.7 | −4.1 | −2.6 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$169M
15 insiders
Of sales under plans
48%
$81.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Guardant Health, Inc. · GH
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $173.25 a share, the company is worth $23.0B.
Source: SEC EDGAR XBRL filings (CIK 0001576280). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.